Insight Molecular Diagnostics (IMDX) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Personalis (PSNL) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 85.0% versus a loss of 10.9%. Over five years, PSNL leads with a -19.5% price change compared with -95.2% for IMDX. Personalis is the larger company by market cap ($1.72 billion vs $107.3 million), about 16.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | PSNL |
|---|---|---|
| Share price | $3.28 | $16.06 |
| Market cap | $107.34M | $1.72B |
| 1-day change | -5.20% | +0.37% |
| YTD return | -56.27% | +101.76% |
| 1-year return | -10.87% | +85.02% |
| 5-year return | -95.18% | -19.46% |
| EPS (TTM) | $-1.52 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $69.65M |
| Revenue growth (YoY) | — | -17.69% |
| Net income (latest FY) | — | $-81.27M |
| Gross margin | — | 22.65% |
| Operating margin | — | -126.43% |
| Net margin | — | -116.69% |
| 52-week high | $8.51 | $18.89 |
| 52-week low | $2.42 | $4.96 |
| Distance from 52-week high | -61.46% | -14.98% |
| Analyst consensus | none | hold |
| Avg. price target upside | +151.52% | -5.54% |
| Average volume | 232.87K | 3.59M |
| Shares outstanding | 32.72M | 106.80M |
| Employees | 55 | 259 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Personalis is about 16.0 times larger than Insight Molecular Diagnostics by market value ($1.72B vs $107.34M).
- PSNL has outperformed IMDX by 95.9 percentage points over the past year.
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Health Care · Medical Specialities · 259 employees
IMDX vs PSNL FAQ
Which is bigger, Insight Molecular Diagnostics or Personalis?
Personalis (PSNL) is larger, with a market capitalization of $1.72B compared with $107.34M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or PSNL?
PSNL returned +85.02% over the past 12 months, compared with -10.87% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Personalis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Insight Molecular Diagnostics and Medical Specialities for Personalis.